Merck & Co., Inc. Target of Unusually High Options Trading (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was the recipient of some unusual options trading activity on Friday. Traders acquired 82,320 call options on the stock. This represents an increase of 77% compared to the average daily volume of 46,456 call options.

Insider Buying and Selling at Merck & Co., Inc.

In other news, Director Inge G. Thulin purchased 2,833 shares of the stock in a transaction dated Thursday, February 6th. The stock was acquired at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares in the company, valued at $258,837.25. This represents a 2,833.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Cristal N. Downing sold 2,361 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $88.76, for a total transaction of $209,562.36. Following the sale, the insider now owns 7,085 shares of the company's stock, valued at approximately $628,864.60. This trade represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Institutional Trading of Merck & Co., Inc.

A number of large investors have recently modified their holdings of the company. Lansforsakringar Fondforvaltning AB publ acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $90,865,000. PKO Investment Management Joint Stock Co acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $4,245,000. Wealthedge Investment Advisors LLC acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $402,000. Campbell Deegan Wealth Management LLC acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $588,000. Finally, Old North State Trust LLC increased its stake in Merck & Co., Inc. by 7.7% during the 4th quarter. Old North State Trust LLC now owns 9,589 shares of the company's stock valued at $954,000 after buying an additional 689 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock traded down $0.35 during trading hours on Friday, reaching $94.36. The company's stock had a trading volume of 5,865,486 shares, compared to its average volume of 10,102,582. The company's 50 day simple moving average is $93.66 and its 200 day simple moving average is $102.14. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a one year low of $81.04 and a one year high of $134.63. The stock has a market cap of $238.35 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.

Remove Ads

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.85 by ($0.13). Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business had revenue of $15.62 billion during the quarter, compared to the consensus estimate of $15.51 billion. During the same quarter in the previous year, the business posted $0.03 earnings per share. The company's quarterly revenue was up 6.8% compared to the same quarter last year. As a group, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. announced that its board has authorized a share buyback program on Tuesday, January 28th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 4.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a $0.81 dividend. The ex-dividend date is Monday, March 17th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.43%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 48.14%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Leerink Partners lowered their price target on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an "outperform" rating for the company in a report on Monday, January 13th. BMO Capital Markets dropped their price target on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a research report on Wednesday, February 5th. Wolfe Research started coverage on shares of Merck & Co., Inc. in a research report on Friday, November 15th. They set a "peer perform" rating for the company. UBS Group dropped their price target on shares of Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Finally, Morgan Stanley dropped their price objective on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and a consensus target price of $117.12.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.